Spots Global Cancer Trial Database for Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

Official Title: Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers

Study ID: NCT01021215

Conditions

Tobacco Use Disorder

Interventions

Zileuton

Celecoxib

laboratory biomarker analysis

Study Description

Brief Summary: The goal of this clinical research study is to learn how zileuton alone or the combination of zileuton and celecoxib may affect certain chemicals in the body that may be linked with a risk for smoking-related lung disease. These effects will be measured by a urine test

Detailed Description: PRIMARY OBJECTIVES: I. To determine whether short-term administration of zileuton, a 5-lipoxygenase (5-LO) inhibitor, in current smokers will suppress the formation of urinary leukotriene E4 (LTE4) and shunt arachidonic acid into the cyclooxygenase (COX) pathway, resulting in elevated urinary prostaglandin E-metabolite (PGE-M). SECONDARY OBJECTIVES: I. To determine whether short-term co-administration of celecoxib, a selective COX-2 inhibitor, and zileuton suppresses levels of both urinary LTE4 and PGE-M in current smokers. II. To evaluate the association between baseline levels of urinary LTE4 and magnitude of the arachidonic acid shunt induced by zileuton. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive zileuton orally (PO) twice daily (BID) on days 1-6. ARM II: Patients receive zileuton as in Arm I and celecoxib PO BID on days 1-6.